Xinbang Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 41.2442 million yuan, a decrease of 29.89%
Xinbang Pharmaceutical released its Q1 2025 performance, with operating revenue of 1.441 billion yuan, a year-on-year decrease of 8.93%; net profit attributable to the parent company of 41.2442 million yuan, a year-on-year decline of 29.89%; net profit excluding non-recurring gains and losses of 41.0754 million yuan, a year-on-year decrease of 30.16%; basic earnings per share of 0.02 yuan
According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its first-quarter report for 2025, showing an operating income of 1.441 billion yuan, a year-on-year decrease of 8.93%. The net profit attributable to shareholders of the listed company was 41.2442 million yuan, a year-on-year decrease of 29.89%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 41.0754 million yuan, a year-on-year decrease of 30.16%. The basic earnings per share were 0.02 yuan
